-
Elecsys® Anti-HAV
Immunoassay for the quantitative determination of total antibodies against HAV
-
Elecsys® Anti-HAV IgM
Immunoassay for the qualitative determination of IgM-antibodies to HAV
-
Elecsys® Anti-HBe
Immunoassay for the qualitative determination of total antibodies against hepatitis B e antigen (HBeAg) -
Elecsys® Anti-HCV II
Immunoassay for the qualitative determination of antibodies against HCV -
Elecsys® Anti-SARS-CoV-2
Immunoassay for the qualitative detection of antibodies (incl. IgG) against SARS-CoV-2 -
Elecsys® Anti-SARS-CoV-2 S
Immunoassay for the quantitative determination of antibodies to the SARS-CoV-2 spike protein -
Elecsys® Anti-TSHR
Elecsys Anti-TSHR (TRAK) is a fully automated test for the detection of autoantibodies to the TSH receptor -
Elecsys® CA 125 II
The Roche Elecsys® CA 125 II assay is a tumour marker test for use with blood samples to support monitoring and surveillance of ovarian cancer patients and together with HE 4 for risk assessment of patients with pelvic mass with the ROMA™ algorithm -
Elecsys® Calcitonin
A powerful tool for the diagnosis and monitoring of medullary thyroid carcinoma (MTC)
-
Elecsys® CMV IgG
Immunoassay for the quantitative determination of IgG-antibodies against CMV -
Elecsys® CMV IgG Avidity
Immunoassay for the qualitative determination of CMV IgG avidity.
-
Elecsys® CMV IgM
Immunoassay for the qualitative determination of IgM-antibodies against CMV
-
Elecsys® HBe Ag
Immunoassay for the qualitative determination of hepatitis B e antigen (HBeAg)
-
Elecsys® HBsAg II
Immunoassay for the qualitative determination of hepatitis B surface antigen (HBsAg) -
Elecsys® HBsAg II quant II
Immunoassay for the quantitative determination of hepatitis B surface antigen (HBsAg) -
Elecsys® HE4 – Human epididymal protein 4
A biomarker for the management of ovarian cancer patients